WO2000041671A2 - Composition, dispositif, et methode pour retirer des matieres adipeuses sous cutanees - Google Patents

Composition, dispositif, et methode pour retirer des matieres adipeuses sous cutanees Download PDF

Info

Publication number
WO2000041671A2
WO2000041671A2 PCT/US1999/029374 US9929374W WO0041671A2 WO 2000041671 A2 WO2000041671 A2 WO 2000041671A2 US 9929374 W US9929374 W US 9929374W WO 0041671 A2 WO0041671 A2 WO 0041671A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
perfluorocarbon
composition
area
group
Prior art date
Application number
PCT/US1999/029374
Other languages
English (en)
Other versions
WO2000041671A9 (fr
WO2000041671A3 (fr
Inventor
Nikolai Tankovich
Original Assignee
T & T Pharmaceuticals, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T & T Pharmaceuticals, Ltd. filed Critical T & T Pharmaceuticals, Ltd.
Publication of WO2000041671A2 publication Critical patent/WO2000041671A2/fr
Publication of WO2000041671A3 publication Critical patent/WO2000041671A3/fr
Publication of WO2000041671A9 publication Critical patent/WO2000041671A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/89—Suction aspects of liposuction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/84—Drainage tubes; Aspiration tips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0476—Oxygenated solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/08—Lipoids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/058—General characteristics of the apparatus combined with other kinds of therapy with ultrasound therapy

Definitions

  • a major concern relating to human skin is the accumulation of excess layers of fat cells, especially in middle age and elderly people, which causes them to appear fatty and older.
  • the present invention provides a composition for use in the removal of tissue and fat from a patient.
  • the composition comprises a perfluorocarbon (PFC) and one or more agents selected from the group consisting of anesthetics and vasoconstrictors.
  • PFC perfluorocarbon
  • the composition can be combined with a pharmaceutical carrier, preferably a pharmaceutical carrier suitable for cosmetic or aesthetic surgical procedures, in particular liposuction, for removal of body fat.
  • a pharmaceutical carrier preferably a pharmaceutical carrier suitable for cosmetic or aesthetic surgical procedures, in particular liposuction, for removal of body fat.
  • Compositions used in the art for such procedures as known as "tumescent solutions.”
  • Vasoconstrictors which are useful in the composition of the invention include but are not restricted to epinephrine, levarterenol, phenylephrine, athyladrianol, ephedrine.
  • Transferosome Compositions of Perfluorocarbons Another aspect of the invention is directed to a transferosome composition which comprises transferosomes which comprise one or more perfluorocarbons (PFCs).
  • Transferosomes are lipid vesicles which have the unique property, unlike conventional lipid suspensions (such as standard liposomes or mixed lipid micelles) of being sufficiently flexible or deformable to pass through pores or other biological apertures which are appreciably smaller than the size of the transferosome (G. Cevc et al., Biochimica et Biophysica Acta 1368:201-215, 1998). Tranferosomes provide the advantage of maximizing, relative to conventional liposomes, the transdermal delivery of a therapeutic agent. Accordingly, an objective of the invention involves providing a composition suitable for topical application to the skin, the composition for transporting therapeutic amounts of perfluorocarbon to the hypodermis to thereby contact and emulgate subcutaneous fat deposits therein.
  • Cevc Lipid properties as a basis for the modeling and design of liposome membranes, in G. Gregoriadis, Ed., Liposome Technology, 2nd ed., CRC -Press, Boca Raton, FL, 1992, pp. 1-36; and in G. Cevc, Material Transport across permeability barriers by means of lipid vesicles in: R. Lipowsky (ed.), Handbook of Physics of Biological Systems, vol. I, Elsevier Science, Chap. 9, 1995, pp. 441-466. A variety of transferosome compositions are described in detail in G. Cevc, 1991, European Patent 91 1 14 163.8-2114).
  • a starting perfluorocarbon solution which is Perftoran contains approximately of 12 mEq of sodium carbonate per liter, 15.2 % perfluorodecalin, 7.6% perfiuoromethylcyclohexypiperidin,4% Proxanol-268, 0.039% potassium chloride, 0.6%) sodium chloride, 0.019% magnesium chloride, 0.028 % calcium chloride, 0.13% sodium hydrocarbonate, 0.02% sodium hydrophosphate, 0.2% glucose, the remainder being water.
  • 82 ml of the starting solution is mixed, for example, with 0.9 g of SPC and approx.
  • Transdermal delivery systems used in the present invention and guidance for combining the transfersome composition comprising PFC of the present invention with transdermal delivery systems are disclosed in detail in generally available references, including Topical Drug Bioa ⁇ 'ailab/ity, Bioequivalence, and Penetration (eds Vinod
  • compositions of the invention in the methods of the invention for removing subcutaneously located fat deposits by applying the compositions in an amorphous form or in the form of a patch to an area of skin for a sufficient period of time to deliver a sufficient amount of PFC to the fat deposits beneath the amplication to emulgate the fat deposits
  • Transdermal delivery systems used in the compositions, methods, and devices of the invention range in design from amo ⁇ hous ointments to solid-state laminates or patches Many transdermal products have reached the marketplace in the world to date (Shah et al., ibid, Table III, p. 31) Categories of solid state laminates or patches include "membrane-controlled,” “reservoir”, “matrix,” or “monolithic” types (Shah et al., ibid, pp 32-33; Schaefer et al., ibid, pp. 214-215) A reservoir is considered a storage place for the drug. The reservoir can be in a polymeric "matrix," in a
  • Liquid form, fill and seal laminate structure e.g. Transdermal Nitro (Summit) and Estraderm (Ciba); Duragesic (Janssen).
  • the present invention is not limited to the above mentioned designs of transdermal systems as new approaches and combinations of each design are possible.
  • all of these systems In combination with PFCs, all of these systems, however, deliver PFCs to the skin surface so that the PFC migrates through the skin to subcutaneous locations of fat deposits.
  • the basic designs and relative advantages and disadvantages are well known to those skilled in the art to allow a transdermal system designer to inco ⁇ orate the most suitable PFC release mechanism for the application required, and to establish efficacy of the transdermal delivery system using methods well known in the art.
  • the transdermal products of the present invention achieve the objective of delivering into the subcutaneous area below the application of the transdermal product an effective amount of perfluorocarbon into subcutaneous fat deposit locations to emulgate said fat deposits.
  • the invention includes methods for removing subcutaneously located fat deposits.
  • the method involves the step of applying a composition comprising perfluorocarbon to an area of skin for a sufficient period of time to deliver a sufficient amount of said perfluorocarbon to the fat deposits beneath the application in order to emulgate the fat deposits.
  • compositions, devices and methods of the inventions find use in modifying the penetrability of the stratum cernuum. When a topical formulation or device is applied to skin, it may produce several effects on the stratum cernuum which will modify the permeability characteristics of the stratum cernuum toward any included drug, such as perfluorocarbon.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition particulière, un dispositif et une méthode permettant de dissoudre des matières adipeuses associées à la peau, ou situées près de la peau. Cette composition concerne des compositions perfluorocarbonées, les dispositifs comprennent des perfluorocarbones pour une application topique sur la peau, et les méthodes comprennent l'injection sous-cutanée ou l'application topique de compositions perfluorocarbonées.
PCT/US1999/029374 1999-01-12 1999-12-09 Composition, dispositif, et methode pour retirer des matieres adipeuses sous cutanees WO2000041671A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23170599A 1999-01-12 1999-01-12
US09/231,705 1999-01-12

Publications (3)

Publication Number Publication Date
WO2000041671A2 true WO2000041671A2 (fr) 2000-07-20
WO2000041671A3 WO2000041671A3 (fr) 2000-11-23
WO2000041671A9 WO2000041671A9 (fr) 2002-04-11

Family

ID=22870339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/029374 WO2000041671A2 (fr) 1999-01-12 1999-12-09 Composition, dispositif, et methode pour retirer des matieres adipeuses sous cutanees

Country Status (1)

Country Link
WO (1) WO2000041671A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2356997A1 (fr) 2005-06-06 2011-08-17 Georgetown University Compositions et procédés de lipomodelage
US20110262562A1 (en) * 2008-10-27 2011-10-27 Lipolyane Aqueous saline solutions for the destruction of fatty tissue
US9888933B1 (en) * 2008-10-14 2018-02-13 Alfredo Ernesto Hoyos Ariza Vaser assisted high definition liposculpture
USD883767S1 (en) 2018-10-10 2020-05-12 A Hoyos Llc Handle
US10980925B1 (en) 2008-10-14 2021-04-20 A Hoyos Llc High definition liposculpture

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455373A (en) * 1994-02-28 1995-10-03 Exfluor Research Corporation Method of producing perfluorocarbon halides
US5637318A (en) * 1992-06-26 1997-06-10 Lancaster Group Ag Dermatological agent for assisting the transport of oxygen in the skin
US5679459A (en) * 1992-06-03 1997-10-21 Alliance Pharmaceutical Corp. Perfluorinated amphiphilic phosphorous compounds: liposomal compositions
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5763423A (en) * 1996-01-04 1998-06-09 Clarion Pharmaeuticals Inc. Pharmaceutical compositions, novel uses, and novel form of tocopherylphosphocholine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5679459A (en) * 1992-06-03 1997-10-21 Alliance Pharmaceutical Corp. Perfluorinated amphiphilic phosphorous compounds: liposomal compositions
US5637318A (en) * 1992-06-26 1997-06-10 Lancaster Group Ag Dermatological agent for assisting the transport of oxygen in the skin
US5455373A (en) * 1994-02-28 1995-10-03 Exfluor Research Corporation Method of producing perfluorocarbon halides
US5763423A (en) * 1996-01-04 1998-06-09 Clarion Pharmaeuticals Inc. Pharmaceutical compositions, novel uses, and novel form of tocopherylphosphocholine

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2356997A1 (fr) 2005-06-06 2011-08-17 Georgetown University Compositions et procédés de lipomodelage
US9888933B1 (en) * 2008-10-14 2018-02-13 Alfredo Ernesto Hoyos Ariza Vaser assisted high definition liposculpture
US10980925B1 (en) 2008-10-14 2021-04-20 A Hoyos Llc High definition liposculpture
US20110262562A1 (en) * 2008-10-27 2011-10-27 Lipolyane Aqueous saline solutions for the destruction of fatty tissue
USD883767S1 (en) 2018-10-10 2020-05-12 A Hoyos Llc Handle

Also Published As

Publication number Publication date
WO2000041671A9 (fr) 2002-04-11
WO2000041671A3 (fr) 2000-11-23

Similar Documents

Publication Publication Date Title
US6302863B1 (en) Method for removal of lipids via a perfluorocarbon tumescent solution
Touitou Drug delivery across the skin
Vitorino et al. Overcoming the skin permeation barrier: challenges and opportunities
Lener et al. Topical anesthetic agents in dermatologic surgery a review
Prausnitz et al. Skin barrier and transdermal drug delivery
Thong et al. Percutaneous penetration enhancers: an overview
Ali et al. The structure of skin and transdermal drug delivery system-a review
Barry Novel mechanisms and devices to enable successful transdermal drug delivery
US6030374A (en) Ultrasound enhancement of percutaneous drug absorption
US20180339166A1 (en) Delivery of large molecular weight biologically active substances
US20060222695A1 (en) Deoxycholic acid liposome-based dermatological topical preparation
Ting et al. Review of traditional and novel modalities that enhance the permeability of local therapeutics across the stratum corneum.
AU2005244096B2 (en) Transdermal administration of phycotoxins
Nounou et al. Liposomal formulation for dermal and transdermal drug delivery: past, present and future
CA2872279C (fr) Compositions topiques de traitement de lipolyse et methodes
Tadicherla et al. Percutaneous dermal drug delivery for local pain control
Dragicevic et al. Invasomes: Vesicles for enhanced skin delivery of drugs
US20060127429A1 (en) Topical numbing composition for laser therapy
EP2435032A1 (fr) Trousse d'administration topique ou transdermique
Kassem et al. Vesicular Nanocarriers: a potential platform for dermal and transdermal drug delivery
Barry Penetration enhancer classification
WO2000041671A2 (fr) Composition, dispositif, et methode pour retirer des matieres adipeuses sous cutanees
Atkinson et al. Targets in dermal and transdermal delivery and classification of penetration enhancement methods
Calpena Campmany et al. Technological, biopharmaceutical and pharmacokinetic advances: new formulations of application on the skin and oral mucosa
Wang et al. Improved dermal delivery of FITC–BSA using a combination of passive and active methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): BR CA CN IL JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): BR CA CN IL JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): BR CA CN IL JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 4/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 4/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase